Bedrijfsoverzicht
Cingulate Inc. is a biopharmaceutical enterprise dedicated to developing pharmaceutical products that leverage proprietary drug delivery platform technology specifically for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety within the United States market. The company operates within the healthcare sector and functions as a biotechnology firm, an industry classification that signifies its focus on the discovery and development of biological therapies rather than established consumer goods or services. As of the latest reported data, the company holds a market capitalization of $66.98M and maintains an employee count of 14 individuals, reflecting a lean organizational structure typical of early-stage development entities. The valuation figure of $66.98M combined with the absence of reported annual revenue indicates that the company's market position is currently defined by investor confidence in its pipeline potential rather than by established commercial sales performance or cash flow generation.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a Net Income of $-22,449,912 and an EBITDA of $-19,397,214, while Revenue remains unreported as N/A in the available data. The substantial gap between the reported Net Income and the EBITDA figures, alongside the unlisted revenue, suggests a cost structure where operating expenses and non-operating costs significantly impact the bottom line before interest and taxes, a characteristic often seen in pre-revenue biotechnology firms. The company reported Free Cash Flow of $-10,425,198, which indicates a consistent burn rate of cash resources required to fund research, development, and operational overheads without current income streams to offset these expenditures. Profitability metrics across all categories are reported at 0.0%, including a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, which collectively indicate that the company has not yet achieved commercial scalability or revenue recognition necessary to generate positive margins. Regarding liquidity and leverage, the company holds $10.95M in cash against $8.79M in debt, resulting in a Debt to Equity ratio of 350.21, which points to a highly leveraged balance sheet relative to its equity base despite the positive net cash position. Short-term liquidity is assessed by a Current Ratio of 1.16, suggesting the company possesses sufficient current assets to cover its current liabilities, though the margin of safety is relatively narrow for a cash-burning entity. Return on Equity stands at -450.6% and Return on Assets is -83.2%, metrics that reveal management has not yet generated positive returns on the capital invested by shareholders or utilized in asset deployment, reflecting the early-stage nature of the business model.
Waarderingsbeoordeling
The valuation multiples for Cingulate Inc. show a P/E Ratio (TTM) as N/A due to the lack of earnings, while the Forward P/E is listed at -3.96, implying that the market is pricing in future profitability expectations that are not yet realized in current financial statements. The Price to Book ratio is 16.65, a figure that indicates the market is valuing the company at a significant premium over its net book value, likely driven by the intangible value of its drug delivery technology and pipeline assets rather than tangible assets. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of -3.34, which suggests that traditional revenue-based or earnings-based valuation models are not applicable until the company transitions from its current development phase to commercialization. The stock's price volatility is contextualized by a 52-Week High of $11.89 and a 52-Week Low of $3.20, with the current trading price situated at a specific point within this wide range that reflects the high uncertainty and speculative nature of biotech equities. The Beta value is recorded at -0.77, an anomalous negative figure that technically suggests an inverse correlation to the broader market, though in practice for such a small-cap stock, it highlights extreme sensitivity to market sentiment and sector-specific news rather than standard market movements.
Growth & Income
Growth metrics for the company are reported as N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), as the lack of historical revenue data prevents the calculation of year-over-year expansion rates. Since the growth rates are unavailable and the company is not currently generating commercial revenue, it is not possible to determine whether earnings are growing faster or slower than revenue in a traditional sense, as the business is still in the investment phase of the product lifecycle. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available resources are being reinvested into the development of its lead product candidate, CTx-1301, rather than being distributed to shareholders. Consequently, the overall growth and income profile of Cingulate Inc. is characterized by a total reliance on capital appreciation driven by future regulatory approvals and clinical trial successes rather than current income generation or dividend payouts.